Horizon Pharma Secures $35,000,000 New Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e166574b-3b7e-49a5-bf62-22afc98baac9&Preview=1 - Date
1/21/2011 - Company Name
Horizon Pharma - Mailing Address
1033 Skokie Boulevard Northbrook, IL 60062 - Company Description
Horizon Pharma, Inc. is a late stage biopharmaceutical company focused on the rapid development and commercialization of therapeutic treatments for mild-to-moderate pain management. The Company is building a novel portfolio of therapies through innovative combinations of approved pharmaceutical products that seek to improve safety, efficacy, and patient compliance. Its lead product candidate, HZT-501, will enter Phase 3 trials in 2007. In addition to HZT-501, Horizon has a pipeline of follow-on pain combination products in earlier stages of development. - Website
http://www.horizontherapeutics.com - Transaction Type
Debt - Transaction Amount
$35,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. - M&A Terms
- Venture Investor
Undisclosed
